摘要
目的观察紫杉醇与长春瑞滨在治疗晚期乳腺癌中的应用及疗效。方法 84例晚期乳腺癌患者,随机分为对照组和观察组组,各42例。对照组患者给予长春瑞滨治疗;观察组患者给予紫杉醇治疗。比较两组患者的治疗效果、中位生存期以及不良反应发生情况。结果观察组治疗有效率为83.3%,高于对照组的64.3%,差异具有统计学意义(P<0.05)。观察组中位生存期为7.5个月,长于对照组的7.3个月,差异具有统计学意义(P<0.05)。两组各不良反应发生率比较差异无统计学意义(P>0.05)。结论在晚期乳腺癌患者临床治疗过程中,采用紫杉醇治疗具有较好的效果,值得在临床上进行推广和应用。
Objective To observe application and curative effects by paclitaxel and vinorelbine in the treatment of advanced breast cancer.Methods A total of84patients with advanced breast cancer were randomly divided into control group and observation group,with42cases in each group.The control group received vinorelbine for treatment,and the observation group received paclitaxel for treatment.Comparison was made on curative effect,median survival time and occurrence of adverse reactions between the two groups.Results The observation group had higher effective rate in treatment as83.3%than64.3%in the control group,and the difference had statistical significance(P<0.05).The observation group had longer median survival time as7.5months than7.3months in the control group,and their difference had statistical significance(P<0.05).Therewas no statistically significant difference of incidence of adverse reactions between the two groups(P>0.05).Conclusion In clinical treatment of advanced breast cancer patients,implement of paclitaxel shows better effect,and it is worth clinical promotion and application.
作者
曾伟明
ZENG Wei-ming(Guangdong Zhuhai City People’s Hospital, Zhuhai 519000, China)
出处
《中国现代药物应用》
2017年第7期113-115,共3页
Chinese Journal of Modern Drug Application
关键词
紫杉醇
长春瑞滨
晚期乳腺癌
Paclitaxel
Vinorelbine
Advanced breast cancer
